Oncoinvent
- Company typePublic
- Founded2010
- HeadquartersOslo, Norway
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Oncoinvent firmographics
Firmographics- Name
- Oncoinvent
- Legal name
- Oncoinvent ASA
- Website
- https://oncoinvent.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Oncoinvent industry classification
Industry- Product category
- Radiopharmaceutical Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where Oncoinvent is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
Oncoinvent business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Revenue model
- Radspherin® Commercialization: Oncoinvent is a clinical-stage biopharmaceutical company with no current revenue. Upon regulatory approval, the company expects to generate revenue through sales of Radspherin® to hospitals and cancer treatment centers. The company was founded by the originators of Algeta and Xofigo (acquired by Bayer for USD 2.9 billion in 2014), indicating expertise in radiopharmaceutical commercialization.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Oncoinvent product offering
Product offeringCore offering
Oncoinvent develops Radspherin®, a clinical-stage, receptor-independent alpha-emitting radiopharmaceutical therapy consisting of inorganic calcium carbonate microparticles as carriers of radium-224 alpha-emitters. It is designed to eradicate residual cancer cells in the peritoneal cavity after cytoreductive surgery via a single targeted dose, initially for ovarian and colorectal cancers with peritoneal metastases. The product is administered intraperitoneally and integrates into existing surgical workflows.
Product overview
Oncoinvent is a clinical-stage Norwegian radiopharmaceutical company developing Radspherin® as its lead product candidate. Radspherin® is a receptor-independent alpha radiation therapy that uses inorganic calcium carbonate microparticles as carriers of radium-224 (Ra-224) alpha-emitters. The product is designed to treat cancer in the peritoneal cavity by delivering highly localized alpha radiation to destroy residual micrometastases after surgical removal of primary tumors. The technology leverages the unique anatomy of the abdominal cavity for targeted delivery, with high-power radiation, short half-life of the radionuclide, and slow-degrading microparticles that ensure regional retention of effective radiation dose. The company is advancing Radspherin® through Phase 2 clinical trials for ovarian cancer and Phase 1/2a trials for colorectal cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- Radspherin® Radspherin® is a receptor-independent alpha-emitting radiopharmaceutical therapy using inorganic calcium carbonate microparticles as carriers of radium-224 alpha-emitters. It is designed to eradicate residual cancer cells in the peritoneal cavity after cytoreductive surgery via a single targeted intraperitoneal dose, initially for ovarian and colorectal cancer patients with peritoneal metastases, and is administered by oncologists and surgical teams at specialized oncology centers.
Quantifiable outcome
- Phase 1 trial in ovarian cancer: All dose levels well tolerated, highest dose selected for further development. 12-month data published in Gynecologic Oncology.
- +3 more outcomes
Companies that use Oncoinvent
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Oncoinvent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Oncoinvent partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- BerGenBiocoreCompleted strategic merger with BerGenBio ASA resulting in uplisting to the Oslo Stock Exchange. The combined entity strengthened financial foundation and advanced clinical development of Radspherin®. Merger involved issuing 117,554,012 shares to former Oncoinvent shareholders. The merger was registered with the Norwegian Register of Business Enterprises and completed October 29, 2025.
- Thor MedicalcoreStrategic thorium-228 supply agreement with Thor Medical. Ensures reliable supply of critical raw material for Radspherin® manufacturing. Thorium-228 is the parent isotope of radium-224 used in Radspherin's alpha-emitting therapeutic.
- ARTBIOminorCollaboration agreement with ARTBIO to collaborate on radiopharma laboratory facilities. Enables sharing of laboratory infrastructure and expertise in radiopharmaceutical development and manufacturing.
- Radiopharmaceutical WholesalercoreDistribution agreement with radiopharmaceutical wholesaler to enable timely and predictable access to Radspherin® for clinical trial sites and patients. Vital part of supply chain infrastructure going forward, without geographical boundaries.
- ScienconsminorResearch collaboration with Sciencons AS resulting in publication of novel method for making 212Pb-labeled monoclonal antibodies using 224Ra-based generator solution in Journal of Nuclear Medicine and Biology.
Scale indicators4 records
Recent moves7 records
Expansion highlights7 records
Oncoinvent competitors and assessment
Company assessmentDirect peers
- Point Biopharma: Point Biopharma was a clinical-to-commercial radiopharmaceutical company developing PSMA-targeted radioligand therapy, acquired by Eli Lilly for approximately USD 1.4 billion in 2023. Comparable as a radioligand therapy developer with a similar M&A exit profile to Oncoinvent's aspiration.
- Fusion Pharmaceuticals: Fusion was a clinical-stage company developing targeted alpha-emitter radioconjugates for cancer treatment, acquired by AstraZeneca in 2024. Directly comparable as a peer in the alpha-emitter radiopharmaceutical space with similar scientific and regulatory challenges.
- Telix Pharmaceuticals: Telix is a publicly listed radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across multiple oncology indications. Directly comparable as a commercial-stage radiopharma with overlapping manufacturing, distribution, and regulatory infrastructure considerations.
- ARTBIO: ARTBIO is an emerging alpha-emitter radiopharmaceutical company with a collaboration agreement with Oncoinvent for laboratory infrastructure sharing. Directly comparable as a peer in the alpha-emitter therapeutic space targeting solid tumors.
- ITM Isotope Technologies Munich: ITM is a privately held radiopharmaceutical company developing targeted radionuclide therapies and producing medical radioisotopes. Directly comparable as a vertically integrated radiopharma combining isotope production with therapeutic product development.
Emerging players
- Radiomedix: Radiomedix is a clinical-stage radiopharmaceutical company developing alpha- and beta-emitting therapeutic agents, with an approved diagnostic agent (Detectnet). Comparable as an emerging peer in the targeted radionuclide therapy space.
Broad incumbents
- Lantheus Holdings: Lantheus is a publicly listed radiopharmaceutical company with approved diagnostic products (e.g., PYLARIFY) and a growing therapeutic pipeline. Comparable as a US-listed radiopharma incumbent navigating similar regulatory and commercialization dynamics.
- Novartis (Pluvicto / Lutathera franchise): Novartis is the leading commercial player in radioligand therapy, with approved products Lutathera (lutetium-177 dotatate) and Pluvicto (lutetium-177 vipivotide tetraxetan). Comparable as the dominant radiopharmaceutical incumbent validating the broader category that Oncoinvent is targeting with a different alpha-emitter approach.
- Bayer (Xofigo): Bayer acquired Algeta, founded by the same team that founded Oncoinvent, for USD 2.9 billion in 2014 to commercialize Xofigo (radium-223), the only approved alpha-emitter radiopharmaceutical. Highly relevant as the precedent acquirer of Oncoinvent's founding team's prior radiopharma venture.
Regional players
- Nordic Nanovector: Nordic Nanovector is a Norwegian clinical-stage biopharmaceutical company developing radioimmunoconjugates for hematologic cancers. Comparable as a regional Norwegian peer in the radioimmunotherapy space with similar early-stage clinical and capital-raising profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Oncoinvent social profiles
Digital presenceOncoinvent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncoinvent leadership team
Management profileNumber of profiles
Profiles6 records
Oncoinvent funding detail
Funding detailFunding overview
Funding rounds4 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncoinvent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncoinvent
What does Oncoinvent do?
Oncoinvent develops Radspherin®, a clinical-stage, receptor-independent alpha-emitting radiopharmaceutical therapy consisting of inorganic calcium carbonate microparticles as carriers of radium-224 alpha-emitters. It is designed to eradicate residual cancer cells in the peritoneal cavity after cytoreductive surgery via a single targeted dose, initially for ovarian and colorectal cancers with peritoneal metastases. The product is administered intraperitoneally and integrates into existing surgical workflows.
Is Oncoinvent a public or private company?
Oncoinvent is a public company. It is classified as public and is currently operating.
When was Oncoinvent founded?
Oncoinvent was founded in 2010. It employs 11 to 50 people.
Where is Oncoinvent based?
Oncoinvent is headquartered in Oslo, Norway, in the Europe region.
How does Oncoinvent make money?
One revenue line is on record: radspherin® Commercialization.
Who are Oncoinvent's main competitors?
Direct peers on record are Point Biopharma, Fusion Pharmaceuticals, Telix Pharmaceuticals, ARTBIO and ITM Isotope Technologies Munich. Radiomedix is listed as an emerging player. Broad incumbents are Lantheus Holdings, Novartis (Pluvicto / Lutathera franchise) and Bayer (Xofigo). Nordic Nanovector is listed as a regional player.
Does Oncoinvent have an API?
No public API is recorded for Oncoinvent.
What industry is Oncoinvent in?
Oncoinvent's product category is Radiopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.